Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of camrelizumab with or without apatinib in PD-L1-positive advanced pulmonary sarcomatoid carcinoma
ChiCTR2000032649Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in lung sarcomatoid carcinoma (PSC), sponsored by First Hospital of China Medical University. Primary endpoint: Objective response rate. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
lung sarcomatoid carcinoma (PSC)
Beyond the preview
Go deeper on ChiCTR2000032649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032649.